What do systematic reviews say?

Continuous infusion vs pulse spray technique

The review found no eligible studies for this question.

• Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pharmacomechanical thrombolysis (Cragg® catheter) vs pulse spray technique

The review found no eligible studies for this question.

• Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Surgical thrombectomy vs pulse spray technique

The review found no eligible studies for this question.

• Interventions for thrombosed haemodialysis arteriovenous fistulas and grafts 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Sodium modelling vs slow dialysis

• Interventions for preventing haemodialysis dysequilibrium syndrome 2024 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 15 participants
  Low

Summary of findings table ‐ High sodium dialysate vs standard sodium dialysate

• Interventions for preventing haemodialysis dysequilibrium syndrome 2024 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 22 participants
  Very low

Standard interferon vs placebo or control

Standard interferon showed no clear difference in death compared with placebo or control (low certainty).

• Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
  RR 0.89 [0.06, 13.23]
  5 studies · 134 participants
  Low

High vs low dose pegylated interferon alpha‐2a or alpha‐2b

The review found no eligible studies for this question.

• Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Standard interferon plus ribavirin vs standard interferon

The review found no eligible studies for this question.

• Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pegylated interferon plus ribavirin vs pegylated interferon alone

The review found no eligible studies for this question.

• Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Direct antivirals (grazoprevir and elbasvir) vs placebo

The review found no eligible studies for this question.

• Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks)

The review found no eligible studies for this question.

• Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pegylated (PEG) interferon alpha‐2a vs standard interferon

Pegylated interferon alpha‐2a showed no clear difference in death compared with standard interferon (low certainty).

• Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
  RR 0.33 [0.01, 7.81]
  1 study · 50 participants
  Low

Self‐management training vs usual care

• Interventions for improving health literacy in people with chronic kidney disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 89 participants
  GRADE not reported

Systemic antibiotics alone vs systematic antibiotics plus antibiotic lock solution

The review found no eligible studies for this question.

• Interventions for treating catheter‐related bloodstream infections in people receiving maintenance haemodialysis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Catheter guidewire exchange vs catheter removal and replacement

The review found no eligible studies for this question.

• Interventions for treating catheter‐related bloodstream infections in people receiving maintenance haemodialysis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Systemic antibiotics plus antibiotic lock solutions plus tissue plasminogen activator vs systemic antibiotics plus antibiotic lock solutions plus heparin

The review found no eligible studies for this question.

• Interventions for treating catheter‐related bloodstream infections in people receiving maintenance haemodialysis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Eculizumab vs placebo or alternative treatment

• Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  100 participants
  Very low

Ravulizumab vs placebo or alternative treatment

• Interventions for atypical haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  58 participants
  Very low

Raloxifene vs placebo

It is very uncertain whether raloxifene changes death compared with placebo (very low certainty).

• Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic… 2021 · Cochrane Headline outcomes only
  RR 1
  2 studies · 110 participants
  Very low

Any anti‐osteoporotic drugs vs placebo

• Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 4973 participants
  Low